Closing Bell Recap: Moderna Inc (MRNA) Ends at 35.15, Reflecting a -16.80 Downturn

Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.

Moderna Inc (NASDAQ: MRNA) closed the day trading at $35.15 down -16.80% from the previous closing price of $42.25. In other words, the price has decreased by -$16.80 from its previous closing price. On the day, 33.44 million shares were traded. MRNA stock price reached its highest trading level at $35.38 during the session, while it also had its lowest trading level at $31.94.

Ratios:

For a better understanding of MRNA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.20 and its Current Ratio is at 4.39. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.

On November 19, 2024, Berenberg started tracking the stock assigning a Hold rating and target price of $42.Berenberg initiated its Hold rating on November 19, 2024, with a $42 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 09 ’24 when Klinger Shannon Thyme sold 529 shares for $44.68 per share. The transaction valued at 23,637 led to the insider holds 20,446 shares of the business.

Klinger Shannon Thyme bought 529 shares of MRNA for $23,637 on Dec 09 ’24. On Dec 03 ’24, another insider, Klinger Shannon Thyme, who serves as the Chief Legal Officer of the company, sold 112 shares for $43.30 each. As a result, the insider received 4,849 and left with 19,837 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 13526352896 and an Enterprise Value of 8014346240. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.67 while its Price-to-Book (P/B) ratio in mrq is 1.13. Its current Enterprise Value per Revenue stands at 1.577 whereas that against EBITDA is -3.393.

Stock Price History:

The Beta on a monthly basis for MRNA is 1.60, which has changed by -0.58643305 over the last 52 weeks, in comparison to a change of 0.22263205 over the same period for the S&P500. Over the past 52 weeks, MRNA has reached a high of $170.47, while it has fallen to a 52-week low of $35.80. The 50-Day Moving Average of the stock is -18.50%, while the 200-Day Moving Average is calculated to be -59.64%.

Shares Statistics:

Over the past 3-months, MRNA traded about 8.19M shares per day on average, while over the past 10 days, MRNA traded about 8393960 shares per day. A total of 385.00M shares are outstanding, with a floating share count of 343.19M. Insiders hold about 10.82% of the company’s shares, while institutions hold 67.53% stake in the company. Shares short for MRNA as of 1734048000 were 39488336 with a Short Ratio of 4.62, compared to 1731628800 on 39863421. Therefore, it implies a Short% of Shares Outstanding of 39488336 and a Short% of Float of 13.5.

Most Popular